Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Chromadex Corp

CDXC
Current price
3.44 USD +0.19 USD (+5.85%)
Last closed 3.25 USD
ISIN US1710774076
Sector Consumer Defensive
Industry Packaged Foods
Exchange NASDAQ
Capitalization 252 097 904 USD
Yield for 12 month +154.81 %
1Y
3Y
5Y
10Y
15Y
CDXC
21.11.2021 - 28.11.2021

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California. Address: 10900 Wilshire Blvd, Los Angeles, CA, United States, 90024

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

6.67 USD

P/E ratio

Dividend Yield

Current Year

+83 570 000 USD

Last Year

+72 050 000 USD

Current Quarter

+22 739 000 USD

Last Quarter

+22 153 000 USD

Current Year

+50 780 000 USD

Last Year

+42 797 000 USD

Current Quarter

+13 693 000 USD

Last Quarter

+13 456 000 USD

Key Figures CDXC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -1 391 000 USD
Operating Margin TTM -1.13 %
PE Ratio
Return On Assets TTM -2.68 %
PEG Ratio
Return On Equity TTM -4.67 %
Wall Street Target Price 6.67 USD
Revenue TTM 85 583 000 USD
Book Value 0.41 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 11.9 %
Dividend Yield
Gross Profit TTM 42 797 000 USD
Earnings per share -0.03 USD
Diluted Eps TTM -0.03 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -1.58 %

Dividend Analytics CDXC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CDXC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:3
Payout Ratio
Last Split Date 13.04.2016
Dividend Date

Stock Valuation CDXC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 48.3092
Enterprise Value Revenue 2.7113
Price Sales TTM 2.9457
Enterprise Value EBITDA -68.3215
Price Book MRQ 8.3552

Financials CDXC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CDXC

For 52 weeks

1.25 USD 4.65 USD
50 Day MA 3.31 USD
Shares Short Prior Month 3 117 906
200 Day MA 2.76 USD
Short Ratio 11.43
Shares Short 2 951 738
Short Percent 6.02 %